The GLP-1 shortage reshaped the peptide landscape more than any single regulatory decision, creating the compounding boom, the telehealth clinic surge, and much of the current news cycle around semaglutide and tirzepatide. Here's the shape of what happened.
Why Demand Outpaced Supply
Semaglutide and tirzepatide were approved for diabetes before demand exploded for weight management use, driven by strong trial results, extensive media coverage, and social media visibility. Manufacturing a complex peptide drug at that scale, requiring specialized production facilities and quality processes, takes years to expand, not months. Demand grew far faster than manufacturers could build new capacity, and the FDA formally added several formulations to its drug shortage list as a result.
How Compounding Filled the Gap
With the drugs officially in shortage, compounding pharmacies became a legal source of semaglutide and tirzepatide using the same active pharmaceutical ingredient, often at meaningfully lower prices than the branded product. This created an entire secondary market, including telehealth companies built specifically around prescribing and dispensing compounded versions, alongside legitimate concerns about inconsistent quality, since compounded products don't go through the same batch-level FDA review as the manufactured drug.
The Manufacturers' Response
Both Novo Nordisk and Eli Lilly, the makers of semaglutide and tirzepatide respectively, expanded manufacturing capacity substantially and pushed the FDA to remove their products from the shortage list once supply caught up, which would narrow the legal basis for compounded copies. They also pursued legal action against some compounders and telehealth companies they alleged were selling products under conditions that didn't meet compounding requirements, including some using salt forms of the drug not present in the approved product.
Where Things Stand
Supply has generally improved compared to the peak of the shortage, and the FDA has moved to restrict copies of formulations no longer considered in shortage, but availability, pricing, and the compounding landscape continue to shift as manufacturing capacity, new competitor drugs, and policy responses evolve. Anyone evaluating a compounded option should check current shortage status directly rather than relying on outdated information, since this is genuinely one of the more fluid areas of pharmaceutical regulation in recent memory.
Lessons From the Shortage
The episode is a useful case study in how quickly a genuinely effective drug class can outstrip the manufacturing infrastructure built to supply it, and how that gap gets filled by a mix of legitimate compounding, less scrupulous operators, and outright counterfeit products, all operating in the same market simultaneously. Distinguishing between those categories required, and still requires, more diligence from patients than simply checking price.